Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A (2009) J Clin Oncol 27: 4188-96 Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA (2011) Biol Psychiatry 70: 425-33 Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ (2014) Clin Cancer Res 20: 1190-203 Prospects and challenges for the development of new therapies for Ewing sarcoma. Grohar PJ, Helman LJ (2013) Pharmacol Ther 137: 216-24 Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE (1998) Hypertension 32: 965-71 Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Brown NJ, Agirbasli M, Vaughan DE (1999) Hypertension 34: 285-90 Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Brown NJ, Nadeau JH, Vaughan DE (1997) Thromb Haemost 77: 522-5 A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J (2007) Am J Kidney Dis 50: 946-51 Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. McMeekin DS, Lisyanskaya A, Crispens M, Oza AM, Braly P, Doering D, Bayever E, Michiels B, Markman M (2009) Gynecol Oncol 114: 288-92 Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. Kim KS, Kumar S, Simmons WH, Brown NJ (2000) J Pharmacol Exp Ther 292: 295-8 A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants. Huang H, Tao YX (2014) Int J Biol Sci 10: 817-24
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.